- Home
- INVA vs BCSF Comparison
INVA vs BCSF Comparison
Compare INVA & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- BCSF
- Stock Information
- Founded
- INVA 1996
- BCSF 2015
- Country
- INVA United States
- BCSF United States
- Employees
- INVA N/A
- BCSF N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- INVA Health Care
- BCSF Finance
- Exchange
- INVA Nasdaq
- BCSF Nasdaq
- Market Cap
- INVA 1.1B
- BCSF 901.0M
- IPO Year
- INVA 2004
- BCSF 2018
- Fundamental
- Price
- INVA $21.98
- BCSF $14.17
- Analyst Decision
- INVA Buy
- BCSF Buy
- Analyst Count
- INVA 5
- BCSF 2
- Target Price
- INVA $36.60
- BCSF $15.50
- AVG Volume (30 Days)
- INVA 903.8K
- BCSF 417.1K
- Earning Date
- INVA 11-05-2025
- BCSF 11-10-2025
- Dividend Yield
- INVA N/A
- BCSF 12.68%
- EPS Growth
- INVA 53.96
- BCSF N/A
- EPS
- INVA 1.52
- BCSF 1.44
- Revenue
- INVA $388,521,000.00
- BCSF $278,347,000.00
- Revenue This Year
- INVA $7.98
- BCSF N/A
- Revenue Next Year
- INVA $11.60
- BCSF N/A
- P/E Ratio
- INVA $13.96
- BCSF $9.87
- Revenue Growth
- INVA 10.14
- BCSF N/A
- 52 Week Low
- INVA $16.52
- BCSF $13.20
- 52 Week High
- INVA $22.76
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- INVA 69.26
- BCSF 56.32
- Support Level
- INVA $20.68
- BCSF $13.91
- Resistance Level
- INVA $22.48
- BCSF $14.22
- Average True Range (ATR)
- INVA 0.69
- BCSF 0.31
- MACD
- INVA -0.01
- BCSF 0.06
- Stochastic Oscillator
- INVA 70.46
- BCSF 96.47
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.